SERIAL PROSTATE SPECIFIC ANTIGEN, FREE-TO-TOTAL PROSTATE SPECIFIC ANTIGEN RATIO AND COMPLEXED PROSTATE SPECIFIC ANTIGEN FOR THE DIAGNOSIS OF PROSTATE CANCER
Purpose: The free-to-total prostate specific antigen (PSA) ratio and complexed PSA have been introduced as adjuncts to total PSA for prostate cancer screening. Little data exist on the use of these tests for serial PSA screening. We compared serial total PSA, the free-to-total PSA ratio and calculated complexed PSA in men diagnosed with prostate cancer and matched controls in a population based study.
Materials and Methods: We identified 90 men diagnosed with prostate cancer between
1988 and 1996 with at least 3 serial serum samples obtained at 2-year intervals who
were participants in the β-Carotene and Retinol Efficacy Trial for the prevention
of lung cancer. Samples were available up to 10 years before diagnosis. A total of
90 age matched men from the same cohort without prostate carcinoma were identified
as controls. Free and total PSA was measured by the Abbott AxSYM † Abbott Laboratories, Abbott Park, Illinois.
Results: Baseline demographics of cases and controls were similar. At baseline and diagnosis the men with prostate cancer had higher total and complexed PSA, and a lower free-to-total PSA ratio than controls. Mean followup was 5.2 years in cases and 5.5 in controls. The yearly change in PSA parameters in cases versus controls was 20.7% versus 3.5% for total, −3.4% versus 0.2% for free-to-total and 21.5% versus 3.4% for complexed PSA (p <0.0001). At diagnosis PSA alone was estimated to perform with more than 90% specificity in our model.
Conclusions: In this population based study total PSA was superior to the free-to-total PSA ratio for predicting the development of prostate cancer. While serial changes in free-to-total PSA ratios with time were statistically significantly different in men diagnosed with prostate cancer and controls, the magnitude of these serial changes were slight enough to render them clinically insignificant.
References
- 1 : Asymptomatic incidence and duration of prostate cancer. Am J Epidemiol1998; 148: 775. Google Scholar
- 2 : Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. New Engl J Med1987; 317: 909. Crossref, Medline, Google Scholar
- 3 : Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. New Engl J Med1991; 324: 1156. Crossref, Google Scholar
- 4 : Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasound. J Urol1994; 152: 1520. Abstract, Google Scholar
- 5 : Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol1988; 139: 1235. Link, Google Scholar
- 6 : Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA1992; 267: 2215. Crossref, Medline, Google Scholar
- 7 : A complex between prostate specific antigen and alpha 1-antichymotrypsin is the major form of prostate specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res1991; 51: 222. Google Scholar
- 8 : Prostate specific antigen in serum occurs predominantly in complex with alpha-1 antichymotrypsin. Clin Chem1991; 37: 1618. Google Scholar
- 9 : Determination of the “reflex range” and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology1997; 49: 19. Google Scholar
- 10 : Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol1998; 159: 5. Link, Google Scholar
- 11 : Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA1998; 279: 1542. Crossref, Medline, Google Scholar
- 12 : Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology1998; 52: 372. Crossref, Medline, Google Scholar
- 13 : Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume. J Urol2000; 163: 119. Link, Google Scholar
- 14 : Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer. Urology1996; 48: 4. Google Scholar
- 15 : Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. New Engl J Med1996; 334: 1150. Google Scholar
- 16 : Practical Nonparametric Statistics. New York: John Wiley & Sons1980. Google Scholar
- 17 : Models for longitudinal data: a generalized estimating equation approach. Biometrics1988; 44: 1049. Google Scholar
- 18 : Random-effects models for longitudinal data. Biometrics1982; 38: 963. Google Scholar
- 19 : A marginal regression modelling framework for evaluating medical diagnostic tests. Stat Med1997; 16: 1263. Google Scholar
- 20 : Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA1993; 270: 860. Crossref, Medline, Google Scholar
- 21 : Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol1999; 161: 1174. Link, Google Scholar
- 22 : Observations on the doubling time of prostate cancer: The use of serial prostate specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer1993; 71: 2031. Google Scholar
- 23 : Prostate-specific antigen as predictor of prostate cancer in black men and white men. J Natl Cancer Inst1995; 87: 354. Crossref, Medline, Google Scholar
- 24 : Two-year stability of free and total PSA in frozen serum samples. Urology1998; 52: 247. Google Scholar
- 25 : The use of percent free prostate specific antigen for staging clinically localized prostate cancer. J Urol1998; 159: 1238. Link, Google Scholar
- 26 : Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. J Urol1999; 162: 1346. Link, Google Scholar
- 27 : A prospective evaluation of plasma prostate specific antigen for detection of prostatic cancer. JAMA1995; 273: 289. Google Scholar
From the Division of Public Health Services, Fred Hutchinson Cancer Research Center and Department of Urology, University of Washington, Seattle, Washington
